33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15823)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7078)
  4. Hematologic Malignancies, Division of (6211)
  5. Center for Hematologic Malignancies (6018)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4873)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15823)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7078)
  4. Hematologic Malignancies, Division of (6211)
  5. Center for Hematologic Malignancies (6018)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TATTON phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
    Meeting Abstract

    Yu, H.; Ahn, M. J.; Kim, S. W.; Cho, B. C.; Sequist, L.; Orlov, S.; Ottesen, L. H.; Verheijen, R. B.; Mellemgaard, A.; Wessen, J.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Network modeling of drug resistance mechanisms and drug combinations in breast cancer
    Meeting Abstract

    Zanudo, J. G. T.; Mao, P.; Montero, J.; Xu, G.; Kowalski, K. J.; Johnson, G. N.; Baselga, J.; Scaltriti, M.; Letai, A. G.; Wagle, N.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Development and validation of a clinical-grade cell-free DNA profiling assay: MSK-ACCESS
    Meeting Abstract

    Tsui, D. W. Y.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Improved progression-free and overall survival (PFS/OS) in patients (pts) with emergence of JTX-2011 associated biomarker (ICOS high CD4 T cells) on the ICONIC trial
    Meeting Abstract

    Yap, T. A.; Gainor, J. F.; Callahan, M. K.; Falchook, G. S.; Pachynski, R. K.; LoRusso, P.; Kummar, S.; Gibney, G. T.; Burris, H. A.; Tykodi, S. S.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial
    Meeting Abstract

    Won, H. H.; Selcuklu, S. D.; Piha-Paul, S. A.; Saura, C.; Rodon, J.; Mayer, I. A.; Loi, S.; Shapiro, G. I.; Lu, J.; Brufsky, A.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Hyperactivation of mTORC1 drives acquired resistance to the pan -HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers
    Meeting Abstract

    Sudhan, D. R.; Guerrero-Zotano, A.; Won, H.; Ericsson, P. G.; Liu, Q.; Dugger, T.; Koch, J.; Schram, A.; Servetto, A.; Cutler, R.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • The Polycomb repressor complex 1 promotes recruitment of myeloid-derived suppressor cells and immune evasion during bone colonization in castration-resistant prostate cancer
    Meeting Abstract

    Su, W.; Zhang, B.; Han, H.; Chakraborty, G.; Zhou, B.; Su, J.; Yang, G.; Ouerfelli, O.; Rosen, N.; Scher, H. I.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Enhancing apoptosis to improve the therapy of EGFR-mutant lung cancer
    Meeting Abstract

    Tanaka, K.; Han, S.; Ganesan, Y. T.; Hsieh, J. J.; Cheng, E. H.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • ARAF activates RAS by antagonizing its interaction with NF1
    Meeting Abstract

    Su, W.; Yaeger, R.; Na, N.; Hechtman, J.; Paroder, V.; Misale, S.; Han, S. W.; Abdel-Wahab, O. I.; McCormick, F.; Rosen, N.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • ARID1A is a critical regulator of luminal identity and therapeutic response in estrogen receptor-positive breast cancer
    Meeting Abstract

    Toska, E.; Xu, G.; Chhangawala, S.; Cocco, E.; Razavi, P.; Otto, J.; Cai, Y.; Chan, C.; D'Avino, D. R.; Collings, C.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save